

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Excelra provides Cellarity access to GOSTAR database for drug discovery

05 November 2020 | News

GOSTAR is the world's largest small molecule medicinal chemistry intelligence platform that encompasses over 8 million compounds



Excelra, a global data science & data analytics company based in Hyderabad, and Cellarity, a US based flagship pioneering company working on the development of a new generation of medicines to treat diseases at the level of cell behaviours, have announced an agreement whereby Excelra will provide Cellarity access to its Global Online Structure Activity Relationship database (GOSTAR).

[GOSTAR](#) is the world's largest small molecule medicinal chemistry intelligence platform that encompasses over 8 million compounds, linking chemical structure to biological, pharmacological and therapeutic activities. With a vast knowledge base of 28 million SAR data points, GOSTAR equips researchers in the early as well as optimization stages of drug discovery.

Cellarity's drug discovery platform uses high-resolution biological data and unique machine learning capabilities to pioneer an entirely new approach to drug discovery. Cellarity is designing medicines that target and change cell behaviors to unlock treatments in a large number of disease areas. "We are looking forward to using high quality annotated GOSTAR data on millions of small molecules, while leveraging Cellarity's proprietary AI/ML modules to generate predictable drug-like molecules that ultimately guide the design of novel Cell Behavior-Targeted therapies. Our preliminary assessment gives us the confidence in the utility of GOSTAR database," said Ramakanth Sarabu, Head of Chemistry, Cellarity.

"GOSTAR is a widely used structure activity relationship database in AI/ML driven drug discovery programs. We strongly believe that this collaboration equips AI/ML and medicinal chemistry researchers at Cellarity to utilize curated interactions of millions of small molecules with potential drug targets to generate novel compounds with desired pharmacological profiles," said Raveendra Dayam, Director, Chemistry Services, Excelra.